ARLNC1 and prostate cancer: For example, the DEG, LINC02532, was recently identified as a marker of radiosensitivity in clear cell renal carcinoma, while ARLNC1, decreased in our data, is associated with maintenance of androgen receptor signalling in prostate cancer [44,45].